Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

The aim of this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with different disease durations and subjects with type 2 and adult-onset type ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Ekberg and colleagues proposed that in type 1 diabetes a deficiency of C peptide, a subunit of the proinsulin molecule, also contributes to nerve damage; their animal studies showed that C-peptide ...

Lucknow: Contrary to the popular belief that black coffee and green team contract blood sugar and improve insulin sensitivity ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

The c-peptide result for Baby L was higher at 264 picomoles per litre, which is well within the range expected for a healthy ...